In 2021, Doan et al. [207] explored the use of a combinatorial drug regimen including TMZ, GPR-17 agonist 2-({5-[3-(Morpholine-4-sulfonyl)phenyl]-4-[4-(trifluoromethoxy)phenyl]-4H-1,2,4-triazol-3-yl}sulfanyl)-N-[4-(propan-2-yl)phenyl]acetamide, and alkylaminophenol against GBM. This evidence concerns the gene GPR17 and glioblastoma.